Download App

Log in to access Online Inquiry
Company Overview More
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson’s disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer’s disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
CEO: Kapusta, Matthew Craig
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > QURE uniQure NV > Detailed Quotes

QURE uniQure NV

13.360-0.360-2.62%
Close 05/23 20:00 ET
High
14.110
Open
13.820
Turnover
3.65M
Low
13.260
Pre Close
13.720
Volume
268.87K
Market Cap
623.21M
P/E(TTM)
1.92
52wk High
38.800
Shares
46.65M
P/E(Static)
1.90
52wk Low
12.520
Float Cap
467.38M
Bid/Ask %
66.67%
Historical High
82.490
Shs Float
34.98M
Volume Ratio
0.74
Historical Low
4.720
Dividend TTM
--
Div Yield TTM
500
P/B
1.14
Dividend LFY
--
Div Yield LFY
3742.51%
Turnover Ratio
0.77%
Amplitude
6.19%
Avg Price
13.571
Lot Size
1
Float Cap
467.38M
Bid/Ask %
66.67%
Historical High
82.490
Shs Float
34.98M
Volume Ratio
0.74
Historical Low
4.720
Dividend TTM
--
P/B
1.14
Dividend LFY
--
Turnover Ratio
0.77%
Amplitude
6.19%
Avg Price
13.571
Lot Size
1
Price Forecast

No Data

News

Comment